List view / Grid view
17 July 2014 | By Teva
Teva Pharmaceutical Industries Ltd. reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director...
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
16 July 2014 | By Biogen Idec
Biogen Idec announced a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis across the country...
15 July 2014 | By kdm communications
Tecan has extended the flexibility of its popular Cavro® Omni Robot with the introduction of embedded control functions and the option to select single axis configurations...
15 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets...
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
14 July 2014 | By Teva
First breath-actuated dry-powder SABA inhaler to be accepted by FDA for review...
14 July 2014 | By Abbott
Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company...
14 July 2014 | By Roche
Roche announced that the Phase III coBRIM study met its primary endpoint...
11 July 2014 | By Innopharma Labs
Glatt and Innopharma Labs enter into a partnership to enable customers to profit from EyeconTM in-line particle characterisation...
11 July 2014 | By Abbott
A proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott has made in China...
11 July 2014 | By Sanofi
Sanofi Pasteur, the vaccines division of Sanofi announced the publication in The Lancet of the detailed results of its first landmark phase III dengue vaccine efficacy study conducted in five countries in Asia...
